title: Biomarkers in pancreatic adenocarcinoma.
abstract: Pancreatic adenocarcinoma is a highly aggressive cancer, with a median patient survival of less than one year. Clinically useful biomarkers capable of accurately assessing prognosis, as well as response to therapy, are urgently needed. At the 2014 ASCO Annual Meeting, Maus et al. (Abstract #e15199) and Neuzillet et al. (Abstract #e15200) present data on use of c-met as a prognostic biomarker, and Shultz et al. (Abstract #4133) use a multiplex antibody panel to identify predictive markers of response to gemcitabine and erlotinib.
authors: Tufts University School of Medicine. Boston, MA, USA. njoza@tuftsmedicalcenter.org.
authors: Nicholas
authors: N
authors: Joza
authors: Muhammad Wasif
authors: MW
authors: Saif
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D002272:Carcinoembryonic Antigen / Q000097:blood; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000097:blood; D010190:Pancreatic Neoplasms / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D011379:Prognosis; D019859:Proto-Oncogene Proteins c-met / Q000235:genetics / Q000378:metabolism; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D019859:Proto-Oncogene Proteins c-met